A device and method are described for draining aqueous humor from the interior of the eye to the exterior of the conjunctiva for reducing intraocular pressure within the eye and, more particularly, an implantable device with a replaceable resistive component is described for regulating the flow of the aqueous humor.
Glaucoma is a group of chronic optic nerve diseases and a leading cause of irreversible blindness. The major risk factor in glaucoma is elevated intraocular pressure due to improper drainage of aqueous humor in the eye. Reduction of intraocular pressure is the only proven treatment to stop the progression of vision loss by reducing stress on the optic nerve.
Standard glaucoma surgeries to reduce intraocular pressure, such as trabeculectomies and glaucoma drainage device implantation, are lengthy and traumatic with unpredictable outcomes and complication rates of 20-60%. Implantable drainage devices function to drain excess aqueous humor from the eye. Installation of a drainage device typically requires a surgical opening made in the sclera to reach the interior of the eye, in particular the anterior chamber or the posterior chamber. The drainage device is then inserted into the interior of the eye for conducting the aqueous humor to the subconjunctival space, herein referred to as subconjunctival shunts, or externally of the conjunctiva, herein referred to as external shunts. A problem associated with subconjunctival shunts is scarring of the bleb in the subconjunctival space affecting its fibrous capsule formation around the outlet, which in many cases requires surgical revision that leads to additional risk of complications. Therefore, there is an ongoing search to identify and utilize alternate drainage sites to avoid many problems associated with bleb and fibrous capsule formations.
External shunts avoid bleb and fibrous capsule formation and the unpredictability of wound healing in the subconjunctival space. However, the outlet of an external shunt may be perceived by the patient as a foreign body, especially those that lie on the corneal surface. These shunts can also be displaced by local tissue motion or extruded by constrictive wound healing processes. One solution secures a subconjunctival portion of the device to the sclera by suturing. However, this technique still leaves the outlet end mobile on the conjunctival surface, which may cause tissue injury and ocular irritation. Moreover, external shunts can expose a mechanical conduit available to transmit microorganisms from the outside to the interior of the eye potentially leading to retrograde infection.
All drainage devices implanted in the eye have the potential to clog from proteins or other substances in the aqueous humor. Clogging reduces permeability of the device and may lead to elevation of intraocular pressure to baseline.
For the foregoing reasons there is a need for a new drainage device for directing aqueous humor from the anterior chamber of an eye to a location external to the eye for reducing and managing intraocular pressure.
An apparatus is provided for draining aqueous humor from an eye for reducing intraocular pressure. The eye has an anterior chamber and includes a cornea, a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer, and an exposed ocular surface of the eye and under eyelids. The draining apparatus comprises a tube extending between an inlet end configured to be disposed at the anterior chamber of the eyeball and an outlet end. The tube defines a passage for fluid flow between the inlet end and the outlet end. An outlet assembly having an inner surface and an outer surface is configured to be disposed such that the inner surface contacts the conjunctival layer externally of the eyeball. The outlet assembly comprises a housing defining a cavity in fluid communication with the outlet end of the tube and having an aperture opening into the cavity for allowing egress of aqueous humor onto the external ocular surface. A resistive component is disposed in the cavity of the housing between the outlet end of the tube and the aperture. The resistive component is configured for providing resistance to a flow of aqueous humor for controlling the flow through the tube from the anterior chamber of the eyeball to the external ocular surface. A pair of tabs project outwardly in opposite directions from the housing. The tabs are adapted to be disposed subconjunctivally for securing the draining apparatus relative to the eyeball.
A method for controlling intraocular pressure within the eye is also provided. The method comprises the step of providing a device for draining aqueous humor from the eye. The draining device comprises a tube extending between an inlet end, the tube defining a passage for fluid flow between the inlet end and the outlet end. An outlet assembly has an inner surface and an outer surface and comprises a housing defining a cavity in fluid communication with the outlet end of the tube and having an aperture opening into the cavity for allowing egress of aqueous humor. A resistive component is disposed in the cavity of the housing between the outlet end of the tube and the aperture. The resistive component is configured for providing resistance to a flow of aqueous humor for controlling the flow through the tube from the anterior chamber of the eyeball to the external ocular surface. A pair of tabs project outwardly in opposite directions from the housing. The method for controlling intraocular pressure further comprises the steps of implanting the draining device in the eye such that aqueous humor flows through the tube from the anterior chamber of the eye to the external ocular surface, and securing the tabs under the conjunctival layer.
For a more complete understanding of the present invention, reference should now be had to the embodiments shown in the accompanying drawings and described below. In the drawings:
Certain terminology is used herein for convenience only and is not to be taken as a limitation on the invention. For example, words such as “upper,” “lower,” “left,” “right,” “horizontal,” “vertical,” “upward,” and “downward” merely describe the configuration shown in the FIGs. Indeed, the components may be oriented in any direction and the terminology, therefore, should be understood as encompassing such variations unless specified otherwise.
Referring now to the drawings, wherein like reference numerals designate corresponding or similar elements throughout the several views, an embodiment of an implantable ocular drainage device is shown in
The tubular body 32 of the drainage device 30 is substantially cylindrical and has a proximal end 42 and a distal end 44. The body 32 defines a lumen 46 that extends between the proximal end 42 and the distal end 44 with the distal end having at least one opening 48 communicating with the lumen 46. The opening 48 functions as a fluid inlet at the distal end 44 of the body 32. The distal end 44 of the body 32 is beveled for easy entry into the anterior chamber of the eye.
The lumen 46 forms at least a portion of a flow path that permits the drainage of aqueous humor from the anterior chamber of the eye to the external surface of the eye. The body 32 has a length sufficient to provide fluid communication between the anterior chamber of the eye and the fornix or cul-de-sac region under the eyelid to allow aqueous humor to flow from the anterior chamber through the lumen 46 and into the tear film when the drainage device 30 is implanted in the eye. For this purpose, the body 32 of the drainage device 30 must have a minimum length of at least about 3 mm for the outlet assembly 34 to reach the fornix or cul-de-sac region under the eyelid. In one embodiment, the body 32 may have a length of between about 4 mm and about 9 mm for adult humans. In use, the body 32 lies substantially underneath the conjunctiva with distal end in the anterior or posterior chamber of the eye as best see in
The transverse cross-sectional shape of the body 32, in addition to circular as shown in
One or more barbs 50 may be provided adjacent the distal end 44 of the body 32. The barbs 50 can extend from a portion of the outer surface of the body 32 for contact with the sclera when the drainage device 30 is implanted. The barbs 50 are adapted to engage with the sclera and provide stability until biointegration of the body 32 within the subconjunctival space. The barbs 50 may be formed as part of the body 32 of the drainage device 30 during manufacture or may be subsequently fused or bonded to the body 32 by suitable means known in the art.
Referring to
The head portion 36 may further comprise integral radial tabs 54 extending outwardly from a longitudinal axis of the drainage device 30. Alternatively, the tabs 54 may be separate pieces attached to the head portion 36. If the tabs 54 are separate pieces, they may be comprised of a flexible biocompatible material, such as silicone or polyurethane, that can easily deform to follow eye movement. As will be described below, the tabs 54 function to stabilize the position of the drainage device 30 and prevent extrusion or pultrusion of the drainage device 30 from its intended location and reduce ocular surface irritation and conjunctival erosion.
Referring to
The filter 40 may be removable and replaceable because access to the outlet assembly 34 is available without disrupting the position of the drainage device 30 in the eye. The filter 40 can be replaced to, for example, adjust the ocular pressure by selecting a filter configuration that provides a selected aqueous humor flow rate. Alternatively, the filter 40 may be configured to form a permanent element of the drainage device 30.
The filter 40 may optionally be provided with a rigid outer sheath 60. In one embodiment, the outer sheath 60 is rigid enough to provide support to the filter 40 in order to assist installation and removal of the filter 40 relative to the head portion 36 and to improve the durability of the filter 40. In one embodiment, the sheath 60 is a hollow mesh cage having a plurality of openings 62 along its perimeter. The openings 62 provide passageways for egress of aqueous humor draining through the filter 40. However, the outer sheath 60 is not limited to this configuration as long as the aqueous humor can pass. For example, the outer sheath 60 may only have one or more openings through a sidewall, or one or more openings through the sidewall and an end wall. The outer sheath 60 may be formed from nitinol, polyimide, or other similar material, such that the combined filter 40 and sheath 60 are expandable following installation to improve sealing of the lumen 46 or the outlet assembly 34.
In one embodiment, the valve 38 comprises a linear slit partially axially traversing the head portion 36 and opening into the interior cavity 52. The slit valve 38 permits the outflow of aqueous humor that has passed through the lumen 46 and the filter 40 to flow onto the sclera and enter the tear film. The slit valve 38 also resists bacterial incursion. While the slit valve 38 depicted in the FIGs. is a single elongate linear aperture, it is understood that other slit configurations may be suitable for providing resistance to aqueous humor outflow and restriction against bacterial incursion. For example, an irregular slit or a plurality of smaller slits may be used, or the slit or plurality of slits may be less elongated and more rounded than shown. A polymer microfluidic passageway in the form of a slit, or a plurality of slits or holes, is also suitable.
The slit valve 38 opens and closes to regulate flow from the interior cavity 52 of the head portion 36 to the external surface of the eye while maintaining the intraocular pressure within the normal range of about 7 mmHg to about 20 mmHg. For example, when the intraocular pressure exceeds a first predetermined pressure, the slit valve 38 will open and permit fluid to exit the outlet assembly 34. When the intraocular pressure reaches a second, lower pressure, the slit valve 38 will close and limit, or inhibit, fluid from exiting the head portion 34. The slit valve 38 will remain closed until the intraocular pressure again reaches the first pressure, and at which time the slit valve 38 will reopen to permit, or enhance, drainage of fluid.
Accordingly, the drainage device 30 provides drainage of the anterior chamber of the eye through the drainage device based on the intraocular pressure and reduces the likelihood for over-draining the anterior chamber and causing hypotony. Additionally, the slit valve 38, with its check valve structure, prevents backflow of the aqueous humor. It is understood that any type of conventional pressure-controlled check valve may be used as long as it has a structure suitable this application.
Referring now to
The tubular body 72 of the drainage device 70 is substantially ovular and has a proximal end 84 and a distal end 86. The body 72 defines a lumen 88 that extends between the proximal end 84 and the distal end 86 with the distal end having at least one opening 90 communicating with the lumen 88 and functioning as a fluid inlet. One or more tapered projections 92, or barbs, may be provided adjacent the distal end 86 of the body 72. A pair of opposed suture bars 94 extend outwardly from the body 72 intermediate along the body 72 between the head portion 76 and the barbs 92.
The head portion 76 of the outlet assembly 74 may further comprise integral radial tabs 96 extending outwardly from a longitudinal axis of the drainage device 30. Referring to
A third embodiment of an implantable ocular drainage device is shown in
The tubular body 102 of the drainage device 100 is substantially ovular and defines a lumen 114 that extends between a proximal end 116 and the distal end 118 of the body. The distal end 118 of the body 102 has at least one opening 120 communicating with the lumen 114 and functioning as a fluid inlet. One or more tapered projections 122, or barbs, may be provided adjacent the distal end 118 of the body 102.
The head portion 106 of the outlet assembly 104 may further comprise integral radial tabs 124 extending outwardly from a longitudinal axis of the drainage device 100. Referring to
Referring now to
The tubular body 142 of the drainage device 140 is substantially circular and has a proximal end 152 and a distal end 154. The body 142 defines a lumen 156 that extends between the proximal end 152 and the distal end 154, with the distal end having at least one opening 156 communicating with the lumen 156 and functioning as a fluid inlet. One or more radial projections 160, or barbs, may be provided adjacent the distal end 154 of the body 142. A pair of opposed suture bars 162 extend outwardly from the body 142 intermediate along the body 142 between the head portion 146 and the barbs 160.
The head portion 146 defines an interior cavity 164 in fluid communication with the lumen 156 of the body 142 for accommodating the filter 150. Referring to
Referring now to
The tubular body 172 of the drainage device 170 is substantially circular in transverse cross-section and has a proximal end 192 and a distal end 194. The body 172 defines a lumen 196 that extends between the proximal end 192 and the distal end 194. A plug 190 operatively connects the proximal end 192 of the body 172 for fluid communication with the outlet assembly 174. The filter 182 is disposed within the head portion 146 such that the lumenal passage of the body 172 is closed or substantially closed by the filter 182. The filter 182 functions to prevent bacterial migration and may be used to regulate intraocular pressure by providing a predetermined resistance to outflow of aqueous humor from the anterior chamber of the eye into the tear film. At least one opening 198 at the distal end 194 of the body 172 communicates with the lumen 196 and functions as a fluid inlet. At least a portion of the tubular body 142 of the drainage device 140 is implantable into the anterior chamber of an eye for draining aqueous humor.
One or more radial barbs 200 may be provided adjacent the distal end 194 of the body 172. A pair of opposed longitudinal suture wings 202 extend radially outwardly from the body 172 intermediate along the length of the body 172 between the head portion 176 and the barbs 200.
A sixth embodiment of an implantable ocular drainage device is shown in
A seventh embodiment of an implantable ocular drainage device is shown in
The filter 252 is disposed within the head portion 245 and is sealed against the flange 249 such that the inlet 249 into the cavity is closed or substantially closed by the filter 252. The filter 252 functions to prevent bacterial migration and may be used to regulate intraocular pressure by providing a predetermined resistance to outflow of aqueous humor from the anterior chamber of the eye into the tear film. The valve 254 in the cap 250 permits the outflow of aqueous humor that has passed through the filter 252 to flow onto the sclera and enter the tear film while providing resistance to aqueous humor outflow and restriction against bacterial incursion.
Referring now to
Referring to
In addition to the materials already described, the body and the outlet assembly of the embodiments of drainage devices 30, 70, 100, 140, 170, 220, 240, 270 may be formed from materials having good biocompatibility and durability and which are sufficiently flexible. Suitable materials include a material selected from the group consisting of silicone, acrylic, polyimide, polypropylene, polymethyl methacrylate, polytetrafluoroethylene, hydrogels, polyolefin, polyolefin resins such as polyethylene, polyisobutylene, ethylene-vinyl acetate copolymer, polynorbornene, polyvinylchloride, polyester, polyvinyl alcohol, polyvinyl pyrolidone, polyethersulfone (PES), poly(styrene-isobutyl-styrene), polysilicon, polyurethane, glass and ceramics such as alumina and titania, metals such as stainless steel, titanium, gold, silver, platinum or nitinol, collagen or chemically-treated collagen, hydroxyapetite, natural and synthetic rubbers such as polybutadiene, polyisoprene, SBR (Styrene Butadiene Rubber), and SIR, polyacetal resin, ABS (Acrylonitrile-Butadiene-Stylene) resin, solid HEMA polymer, and combinations thereof.
At least a portion of the filters 40, 80, 110, 150, 182, 252, 278 has a pore size that is sufficiently small to prevent ingress of microorganisms, such as bacteria, viruses, fungi and spores thereof, from entering the lumen 46 for minimizing the opportunity for reflux infection. A pore size of less than about 0.4 μm is sufficiently small to prevent ingress of microorganisms. In some embodiments, the filter 40, 80, 110, 150, 182, 252, 278 comprise a microporous/nanoporous membrane or polymer network, fiber network, or microcapsular material having a network of pores. Microporous filter membranes suitable for use with ophthalmic devices include micropore filter membranes (polycarbonate, polyethersulfone, polyvinylidene fluoride), porous hydrogels (polyacrylamide, alginate, polyhydroxyethylmethacrylate), and microperforated silicone or polyvinyl polymer, such as polyvinyl alcohol which is expandable within the lumen 46. Other suitable polymers include a polyolefin polymer, an ethylene-vinyl alcohol copolymer, a polyacrylonitrile polymer, a cellulose polymer, cellulose acetate polymer, and a polyamide polymer. Filter membrane nanotechnology may also be useful to fabricate microporous membranes to be biocompatible, non-degradable, and immunoisolating. Other materials, such as ceramics, polymers and metals, such as titanium, may also be suitable for the filter. The filters may be created using lithography or electrospinning.
The filter 40, 80, 110, 150, 182, 252, 278 may have an antibiotic coating to prevent contamination during replacement. Suitable coatings for the filter are described in co-pending U.S. Patent Application Publication No. 2010/0057055, the contents of which are hereby incorporated by reference in their entirety.
At least a portion of the external surfaces of the body, the tabs, and inner surface of the head portion of the drainage devices 30, 70, 100, 140, 170, 220, 240, 270 may be coated with a porous cellular ingrowth coating. The porous cellular ingrowth coating is coated on at least the portion of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 that is in contact with the sclera and conjunctiva when the drainage device is implanted. The porous cellular ingrowth coating may be a hydroxyapatite or porous polyethylene that serves to promote cell adhesion. Selected growth factors may be adsorbed onto this coating to enhance cellular ingrowth. The coating is receptive to tissue attachment so that the body and the tabs, suture bars and suture wings of the drainage devices 30, 70, 100, 140, 170, 220, 240, 270 may be securely anchored in position. This feature enables the drainage devices 30, 70, 100, 140, 170, 220, 240, 270 to resist in situ motion and displacement. To further promote tissue ingrowth and cell attachment, the body of the drainage devices 30, 70, 100, 140, 170, 220, 240, 270 may include surface alterations, such as texturing, roughening or other patterned or non-patterned irregularities.
The remaining surfaces of the drainage devices 30, 70, 100, 140, 170, 220, 240, 270, including the entire lumenal surface, the portions of the external surface of the drainage device not in contact with the sclera, and the filter surfaces, may be coated with a bio-inert surface coating to enhance surface biocompatibility. Such coatings may include bio-inert polymer coatings such as phosphoryl choline (PC) and polyethylene oxide (PEO). Both PC and PEO polymer coatings down regulate deleterious biological reactions, primarily by attracting a large and stable hydration shell when grafted onto a surface. Bio-inert surface coatings may be further modified with biologically active molecules such as heparin, spermine, surfactants, proteases or other enzymes, or other biocompatible chemicals amendable to surface immobilization. PEO also is amendable to end-group coupling for surface immobilization of the biologically active molecules. The addition of such bioactive molecules could advantageously impart specific desired functionality, for example, allowing a further increase in the hydrophilicity of the surface.
The coating for the drainage devices 30, 70, 100, 140, 170, 220, 240, 270 can also comprise material that includes a therapeutic agent as well as antifibrotic and antimicrobial agents. The therapeutic agent can be selected from the group consisting of heparin, selenium, TGF-beta, an intraocular pressure-lowering drug, and an anti-proliferative agent. The coatings can be, for example, a drug eluting coating, an antithrombogenic coating, and a lubricious coating. Materials that may be used for a drug-eluting coating include parylene C, poly(butyl methacrylate), poly(methyl methacrylate), polyethylene-co-vinyl acetate, and other materials known in the art. In addition, these agents may incorporated into the filter material via covalent, metallic, ionic, or non-covalent bonding.
All embodiments of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 described herein may be surgically implanted under topical anesthesia, possibly supplemented subconjunctivally. In general, the drainage device 30, 70, 100, 140, 170, 220, 240, 270 may be inserted into the sclera using routine operative procedures.
Referring to
The conjunctiva is then dissected down from the fornix incision to the limbus to expose the underlying sclera for insertion of the distal end 44 of the tube 32. A needle, trocar, scalpel, or any of a multitude of instruments familiar to ophthalmologic practitioners may be used at the site of the now exposed sclera to make a stab incision through the sclera into the anterior chamber. The pointed tip at the distal end 44 of the body 32 is then inserted through the scleral tract of the incision and into the anterior chamber or posterior chamber of the eye. The remainder of the body 32 remains positioned external to the ocular surface of the eye. Optionally, the body 32 may be sutured to the sclera.
Next, two parallel cuts are made into the conjunctiva adjacent the outlet assembly 34 approximately 2 mm to 4 mm apart. A tab 54 is inserted into each cut. The tabs 54 may be sutured to the sclera with a 10-0 nylon suture. A suture is then used to close the conjunctiva around the tabs 54 while leaving the intermediate portion of the outlet assembly 34 exposed. In some embodiments, holes may be provided in the tabs for additional sutures into the sclera, providing further stability to the drainage device 30 until the biointegration is complete. Similarly, for embodiments of the drainage device 70, 150, 170 including suture bars 94162 or suture wings 202, the suture bars 94, 162 or suture wings 202 are sutured into the sclera for securing the body of the device. The conjunctiva is then restored and the incision is closed with a suture using a known method or a biologically acceptable adhesive. For drainage devices 100, 220, 240, 270 with lips or rims or a conduit, a purse-string 8-0 suture may be used to close the conjunctiva tightly around the outlet.
In use, aqueous humor flows into the drainage device 30 from the anterior chamber or posterior chamber of the eye and passes through the body 32 via the lumen 46 and through the filter 40 and drains via the slit valve 38 in the outlet assembly 34. As described above, the flow path through the drainage device 30 can be configured for regulating drainage of aqueous humor at a predetermined rate and further for resisting the incursion of microorganisms. The outflow of aqueous humor is consistently regulated by the filter 40 and valve 38, either separately or in combination, so that a predictable outflow rate can be calculated for proper drainage for maintaining intraocular pressure of about 6 mmHg to about 18 mmHg. The flow rate will range based on aqueous humor production, which is usually between about 1 uL/min and about 4 uL/min, while avoiding hypotony at less than about 5 mmHg. The dual filter-valve mechanism provides a physiologic design to control pressure in the eye. The valve functions as an episcleral venous pressure device to provide a lower pressure limit. The filter provides resistance in the manner of the trabecular meshwork in a human eye. The combination provides a natural pressure change based on diurnal changes in aqueous humor production and ocular pulse. Thus, the embodiments of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 described herein effectively provide outflow characteristics which model the aqueous humor dynamics of a healthy eye.
The filter 40, 80, 110, 150, 182, 252, 278 can be replaced if there is deterioration or damage over the course of using the drainage device as the protein or other substances contained in the aqueous humor clog the filter. The slit valves or removable caps permit access to the filter 40, 80, 110, 150, 182, 252, 278 so that the filter can be removed and replaced. Accordingly, the filter 40, 80, 110, 150, 182, 252, 278 can be replaced with a new replacement filter by removing the old filter and inserting a new filter via the slit valve or caps. In this way, the intraocular pressure relieving effect of the drainage devices 30, 70, 100, 140, 170, 220, 240, 270 can be sustained for extended periods of time. Because only the filter is replaced, the cost of replacement is much cheaper than the case where the drainage device needs to be re-installed entirely.
In another embodiment, the head portion of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 may be provided with an access port (not shown) so that access to the filter would be available without disrupting the position of the head portion. The access port could, in certain embodiments, be integrated with the slit valve. Other arrangements may be readily envisioned by those skilled in the art.
The embodiments of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 described herein may comprise any of the materials previously described above. The drainage device 30, 70, 100, 140, 170, 220, 240, 270 can be fabricated through conventional micro machining techniques or through procedures commonly used for fabricating optical fibers. For example, in some embodiments, the drainage devices 30, 70, 100, 140, 170, 220, 240, 270 are drawn with a bore, or lumen, extending therethrough. In some embodiments, the tapered tip at the distal end of the body can be constructed by shearing off an end of the tubular body. This can create the tapered portion that can be used to puncture or incise the eye tissue during implantation and dilate the puncture or incision during advancement of the drainage device 30, 70, 100, 140, 170, 220, 240, 270. Other methods of manufacturing the drainage device 30 can be used.
Each of the embodiments of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 provides a method for treating glaucoma wherein aqueous humor is permitted to flow out of an anterior chamber or posterior chamber of the eye through a surgically implanted pathway to an external ocular surface. The drainage device 30, 70, 100, 140, 170, 220, 240, 270 is implanted with minimal invasiveness of the ocular tissue and minimal sense of a foreign object. Immobilizing the outlet assembly of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 is an important feature. Immobilization is enhanced by using a biocompatible material and providing the portions of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 in contact with eye tissue with the porous cellular ingrowth surface to promote tissue integration to the sclera. Coating the surface of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 with polymers or biologically active molecules or providing active agents within the polymers also promotes surface biocompatibility or immobilization post-implantation. All of these features contribute to minimizing problems caused by eye movement (micromotion), including a feeling of invasiveness to the ocular tissues, pain, and displacement of the drainage device 30, 70, 100, 140, 170, 220, 240, 270. Eliminating micromotion prevent adverse events such as fibrosis, erosion, exposure, and/or extrusion.
In addition, the embodiments of the drainage device 30, 70, 100, 140, 170, 220, 240, 270 as described herein can be used to treat other ocular disorders in addition to glaucoma. In one embodiment, the drainage device 30, 70, 100, 140, 170, 220, 240, 270 is used to treat dry eye, wherein the aqueous humor exiting the drainage device combines with the tear film for enhancing moisture and lubrication in the eye.
Although the present device has been shown and described in considerable detail with respect to only a few exemplary embodiments thereof, it should be understood by those skilled in the art that we do not intend to limit the device to the embodiments since various modifications, omissions and additions may be made to the disclosed embodiments without materially departing from the novel teachings and advantages of the device, particularly in light of the foregoing teachings. Accordingly, we intend to cover all such modifications, omission, additions and equivalents as may be included within the spirit and scope of the device as defined by the following claims. In the claims, means-plus-function clauses are intended to cover the structures described herein as performing the recited function and not only structural equivalents but also equivalent structures. Thus, although a nail and a screw may not be structural equivalents in that a nail employs a cylindrical surface to secure wooden parts together, whereas a screw employs a helical surface, in the environment of fastening wooden parts, a nail and a screw may be equivalent structures.
This application is a continuation of U.S. patent application Ser. No. 14/473,228, filed Aug. 29, 2014, the contents of which are incorporated entirely herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3788327 | Donowitz et al. | Jan 1974 | A |
4886488 | White | Dec 1989 | A |
5041081 | Odrich | Aug 1991 | A |
5127901 | Odrich | Jul 1992 | A |
5171213 | Price, Jr. | Dec 1992 | A |
5300020 | L'Esperance, Jr. | Apr 1994 | A |
5346464 | Camras | Sep 1994 | A |
5626558 | Suson | May 1997 | A |
5656026 | Joseph | Aug 1997 | A |
5743868 | Brown | Apr 1998 | A |
5807302 | Wandel | Sep 1998 | A |
5830173 | Avery et al. | Nov 1998 | A |
5882327 | Jacob | Mar 1999 | A |
6077299 | Adelberg et al. | Jun 2000 | A |
6261256 | Ahmed | Jul 2001 | B1 |
6537241 | Odland | Mar 2003 | B1 |
6544208 | Ethier et al. | Apr 2003 | B2 |
6558342 | Yaron et al. | May 2003 | B1 |
6595945 | Brown | Jul 2003 | B2 |
6881198 | Brown | Apr 2005 | B2 |
7118547 | Dahan | Oct 2006 | B2 |
7135009 | Tu et al. | Nov 2006 | B2 |
7156821 | Dohlman | Jan 2007 | B2 |
7186233 | Dohlman | Mar 2007 | B2 |
7192412 | Zhou et al. | Mar 2007 | B1 |
7458953 | Peyman | Dec 2008 | B2 |
7641627 | Camras et al. | Jan 2010 | B2 |
7670310 | Yaron et al. | Mar 2010 | B2 |
8579848 | Field et al. | Nov 2013 | B2 |
8628492 | Lin et al. | Jan 2014 | B2 |
8632489 | Ahmed | Jan 2014 | B1 |
8753305 | Field et al. | Jun 2014 | B2 |
8986240 | Dos Santos et al. | Mar 2015 | B2 |
8998838 | Yalamanchili | Apr 2015 | B2 |
9072588 | Böhm et al. | Jul 2015 | B2 |
9101445 | Bigler et al. | Aug 2015 | B2 |
9132034 | Dos Santos | Sep 2015 | B2 |
9155653 | Field | Oct 2015 | B2 |
9186274 | Camras et al. | Nov 2015 | B2 |
9226851 | Gunn | Jan 2016 | B2 |
9259353 | Dos Santos et al. | Feb 2016 | B2 |
9333115 | Dos Santos | May 2016 | B2 |
9339187 | Rickard | May 2016 | B2 |
9381301 | Lattanzio et al. | Jul 2016 | B2 |
9456924 | Noroozi et al. | Oct 2016 | B2 |
9492321 | Gunn et al. | Nov 2016 | B2 |
9572712 | Gunn | Feb 2017 | B2 |
9622910 | Field et al. | Apr 2017 | B2 |
9681983 | Lind | Jun 2017 | B2 |
20020143284 | Tu et al. | Oct 2002 | A1 |
20020169468 | Brown | Nov 2002 | A1 |
20040073156 | Brown | Apr 2004 | A1 |
20040127843 | Tu et al. | Jul 2004 | A1 |
20040215126 | Ahmed | Oct 2004 | A1 |
20040249441 | Miller et al. | Dec 2004 | A1 |
20040254521 | Simon | Dec 2004 | A1 |
20050049578 | Tu et al. | Mar 2005 | A1 |
20050119737 | Bene | Jun 2005 | A1 |
20050240142 | Dohlman | Oct 2005 | A1 |
20050240143 | Dohlman | Oct 2005 | A1 |
20060036207 | Koonmen et al. | Feb 2006 | A1 |
20060069340 | Simon | Mar 2006 | A1 |
20060116626 | Smedley et al. | Jun 2006 | A1 |
20060189915 | Camras | Aug 2006 | A1 |
20060235367 | Takashima | Oct 2006 | A1 |
20070004998 | Rodgers et al. | Jan 2007 | A1 |
20070156079 | Brown | Jul 2007 | A1 |
20070254005 | Pathak et al. | Nov 2007 | A1 |
20080228127 | Bums et al. | Sep 2008 | A1 |
20090036818 | Grahn et al. | Feb 2009 | A1 |
20090117166 | Myung et al. | May 2009 | A1 |
20090326432 | Schmidt et al. | Dec 2009 | A1 |
20100056979 | Smedley et al. | Mar 2010 | A1 |
20100057055 | Camras | Mar 2010 | A1 |
20100114006 | Baerveldt | May 2010 | A1 |
20110071456 | Rickard | Mar 2011 | A1 |
20110105986 | Bronstein et al. | May 2011 | A1 |
20120302861 | Marshall et al. | Nov 2012 | A1 |
20130096483 | Dacquay | Apr 2013 | A1 |
20130150775 | Dos Santos et al. | Jun 2013 | A1 |
20130150776 | Bohm et al. | Jun 2013 | A1 |
20130150777 | Böhm et al. | Jun 2013 | A1 |
20130150778 | Dos Santos | Jun 2013 | A1 |
20130150779 | Field | Jun 2013 | A1 |
20130218064 | Rickard | Aug 2013 | A1 |
20130317412 | Dacquay et al. | Nov 2013 | A1 |
20130317413 | Field et al. | Nov 2013 | A1 |
20140005587 | Gelvin et al. | Jan 2014 | A1 |
20140066832 | Ovchinnikov et al. | Mar 2014 | A1 |
20140081195 | Clauson | Mar 2014 | A1 |
20140163448 | Lind et al. | Jun 2014 | A1 |
20140171777 | Sanchez et al. | Jun 2014 | A1 |
20150045716 | Gallardo Inzunza | Feb 2015 | A1 |
20150057595 | Gunn et al. | Feb 2015 | A1 |
20150057596 | Lind et al. | Feb 2015 | A1 |
20150057597 | Johnson et al. | Feb 2015 | A1 |
20150202082 | Ilios et al. | Jul 2015 | A1 |
20150230983 | Johnson | Aug 2015 | A1 |
20150230984 | Gunn | Aug 2015 | A1 |
20150257931 | Sanchez et al. | Sep 2015 | A1 |
20150265469 | Olson et al. | Sep 2015 | A1 |
20160033270 | Camras et al. | Mar 2016 | A1 |
20160058615 | Camras et al. | Mar 2016 | A1 |
20160058616 | Camras et al. | Mar 2016 | A1 |
20160067092 | Lind et al. | Mar 2016 | A1 |
20160235298 | Gunn | Aug 2016 | A1 |
20160242962 | Torello et al. | Aug 2016 | A1 |
20160296371 | Gelvin | Oct 2016 | A1 |
20170348148 | Bigler et al. | Dec 2017 | A1 |
20170348149 | Stergiopulos et al. | Dec 2017 | A1 |
20180078416 | Christiansen | Mar 2018 | A1 |
20180092774 | Mehta | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
2 896 386 | Jul 2015 | EP |
2009105573 | Aug 2009 | WO |
2013155252 | Oct 2013 | WO |
2014036437 | Mar 2014 | WO |
2014130574 | Aug 2014 | WO |
2016100500 | Jun 2016 | WO |
2017059272 | Apr 2017 | WO |
2017106517 | Jun 2017 | WO |
2018009556 | Jan 2018 | WO |
Entry |
---|
International Search Report mailed in PCT/US17/40738 dated Nov. 2, 2017, 4 pages. |
International Search Report mailed in PCT/US16/054828 dated Dec. 13, 2016, 1 page. |
International Search Report and Written Opinion mailed in PCT/US18/029717 dated Sep. 21, 2018, 20 pages. |
Dohlman et al., “Shunts to Divert Aqueous Humor to Distant Epithelialized Cavities After Keratoprosthesis Surgery”, Glaucoma, 2010, 19(2), 111-115. |
Molteno et al., “Otago Glaucoma Surgery Outcome Study: Factors Controlling Capsule Fibrosis around Molteno Implants with Histopathological Correlation”, The American Academy of Opthalmology, 2003, 110(11), 2198-2206. |
Number | Date | Country | |
---|---|---|---|
20180325733 A1 | Nov 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14473228 | Aug 2014 | US |
Child | 16043099 | US |